Enfortumab vedotin in metastatic urothelial carcinoma: the solution EVentually?
Metastatic urothelial carcinoma (mUC) is an aggressive malignancy with a dismal prognosis. Enfortumab vedotin (EV) is an antibody-drug conjugate consisting of an antibody targeting Nectin-4. This protein is highly expressed in UC cells. After binding, monomethyl auristatin E is released into cells,...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-09-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2023.1254906/full |
| _version_ | 1797687083628756992 |
|---|---|
| author | Brigida Anna Maiorano Martina Catalano Evaristo Maiello Giandomenico Roviello |
| author_facet | Brigida Anna Maiorano Martina Catalano Evaristo Maiello Giandomenico Roviello |
| author_sort | Brigida Anna Maiorano |
| collection | DOAJ |
| description | Metastatic urothelial carcinoma (mUC) is an aggressive malignancy with a dismal prognosis. Enfortumab vedotin (EV) is an antibody-drug conjugate consisting of an antibody targeting Nectin-4. This protein is highly expressed in UC cells. After binding, monomethyl auristatin E is released into cells, causing UC cell death. EV has been approved as a single agent for pre-treated mUC, with interesting improvements in response rate and survival in a setting with limited treatment options. More recently, EV approval occurred in cisplatin-ineligible naïve mUC patients in combination with pembrolizumab. Our review aims to summarize the pharmacological properties, clinical studies, and future developments of EV in mUC. |
| first_indexed | 2024-03-12T01:14:08Z |
| format | Article |
| id | doaj.art-df894699978d4c0a9429f227930c59d6 |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-03-12T01:14:08Z |
| publishDate | 2023-09-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-df894699978d4c0a9429f227930c59d62023-09-13T22:18:56ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2023-09-011310.3389/fonc.2023.12549061254906Enfortumab vedotin in metastatic urothelial carcinoma: the solution EVentually?Brigida Anna Maiorano0Martina Catalano1Evaristo Maiello2Giandomenico Roviello3Oncology Unit, IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, ItalyDepartment of Health Sciences, Section of Clinical Pharmacology and Oncology, University of Florence, Florence, ItalyOncology Unit, IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, ItalyDepartment of Health Sciences, Section of Clinical Pharmacology and Oncology, University of Florence, Florence, ItalyMetastatic urothelial carcinoma (mUC) is an aggressive malignancy with a dismal prognosis. Enfortumab vedotin (EV) is an antibody-drug conjugate consisting of an antibody targeting Nectin-4. This protein is highly expressed in UC cells. After binding, monomethyl auristatin E is released into cells, causing UC cell death. EV has been approved as a single agent for pre-treated mUC, with interesting improvements in response rate and survival in a setting with limited treatment options. More recently, EV approval occurred in cisplatin-ineligible naïve mUC patients in combination with pembrolizumab. Our review aims to summarize the pharmacological properties, clinical studies, and future developments of EV in mUC.https://www.frontiersin.org/articles/10.3389/fonc.2023.1254906/fullenfortumab vedotinADCantibody-drug conjugatenectin-4urothelial carcinomabladder cancer |
| spellingShingle | Brigida Anna Maiorano Martina Catalano Evaristo Maiello Giandomenico Roviello Enfortumab vedotin in metastatic urothelial carcinoma: the solution EVentually? Frontiers in Oncology enfortumab vedotin ADC antibody-drug conjugate nectin-4 urothelial carcinoma bladder cancer |
| title | Enfortumab vedotin in metastatic urothelial carcinoma: the solution EVentually? |
| title_full | Enfortumab vedotin in metastatic urothelial carcinoma: the solution EVentually? |
| title_fullStr | Enfortumab vedotin in metastatic urothelial carcinoma: the solution EVentually? |
| title_full_unstemmed | Enfortumab vedotin in metastatic urothelial carcinoma: the solution EVentually? |
| title_short | Enfortumab vedotin in metastatic urothelial carcinoma: the solution EVentually? |
| title_sort | enfortumab vedotin in metastatic urothelial carcinoma the solution eventually |
| topic | enfortumab vedotin ADC antibody-drug conjugate nectin-4 urothelial carcinoma bladder cancer |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2023.1254906/full |
| work_keys_str_mv | AT brigidaannamaiorano enfortumabvedotininmetastaticurothelialcarcinomathesolutioneventually AT martinacatalano enfortumabvedotininmetastaticurothelialcarcinomathesolutioneventually AT evaristomaiello enfortumabvedotininmetastaticurothelialcarcinomathesolutioneventually AT giandomenicoroviello enfortumabvedotininmetastaticurothelialcarcinomathesolutioneventually |